RxDoctor Payments Data

Eduardo Garcia, MD

Family Medicine · Moreno Valley, CANPI 1114085065

Payments from drug & device makers

$2,001in general payments, 2019–2025

Across 158 payments — averaging $12.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$457
  • Novo Nordisk$299
  • GSK$215
  • AstraZeneca$148
  • Abbott$138
  • Merck$130
  • plus $615 from 15 others

What the payments were for

  • Food & beverage$2,001100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,001 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$37,679
Medicare patients
134
Services billed
1,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin326$282,414
OzempicSemaglutide142$143,732
JanuviaSitagliptin Phosphate157$137,017
EliquisApixaban136$110,152
TrulicityDulaglutide101$95,132
TradjentaLinagliptin69$55,662
CreonLipase/Protease/Amylase36$49,335
XareltoRivaroxaban52$44,302
RybelsusSemaglutide32$38,966
MounjaroTirzepatide28$28,484
LinzessLinaclotide44$26,080
ProliaDenosumab13$21,752
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$17,859
FarxigaDapagliflozin Propanediol19$17,007
Tresiba Flextouch U-200Insulin Degludec20$13,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$111$338,077395 claims
Novo NordiskOzempic, Rybelsus$299$182,698174 claims
MerckJanuvia$130$137,017157 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$65$126,950165 claims
PfizerEliquis$41$110,152136 claims
AbbVieCreon, Linzess$457$75,41580 claims
Johnson & JohnsonXarelto, Invokana$87$55,94663 claims
GSKTrelegy Ellipta$215$17,85925 claims
AstraZenecaFarxiga$148$17,00719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Moreno Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →